Spots Global Cancer Trial Database for advanced gastric adenocarcinoma
Every month we try and update this database with for advanced gastric adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma | NCT04977193 | Advanced Gastri... | LY011 | 18 Years - 70 Years | Shanghai Longyao Biotechnology Inc., Ltd. | |
| Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer | NCT04675866 | Advanced Gastri... | Camrelizumab, A... | 18 Years - 75 Years | Henan Cancer Hospital | |
| Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy | NCT02448329 | Advanced Gastri... | AZD1775 paclitaxel | - 20 Years | Samsung Medical Center | |
| Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment | NCT02447380 | Advanced Gastri... | AZD6094 Docetaxel | - 20 Years | Samsung Medical Center | |
| Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment | NCT02447406 | Advanced Gastri... | AZD6094 docetaxel | - 20 Years | Samsung Medical Center | |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | NCT06203600 | Advanced Esopha... Advanced Gastri... Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Esop... Metastatic Gast... Metastatic Gast... Unresectable Es... Unresectable Ga... Unresectable Ga... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Nivolumab Paclitaxel Questionnaire A... Ramucirumab | 18 Years - | National Cancer Institute (NCI) | |
| Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy | NCT02448329 | Advanced Gastri... | AZD1775 paclitaxel | - 20 Years | Samsung Medical Center | |
| Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy | NCT04993378 | Advanced Gastri... Immunotherapy | EV-array | 18 Years - | Peking University | |
| Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma | NCT03159819 | Advanced Gastri... Pancreatic Aden... | CAR-CLD18 T Cel... | 18 Years - 70 Years | Changhai Hospital | |
| Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma | NCT03159819 | Advanced Gastri... Pancreatic Aden... | CAR-CLD18 T Cel... | 18 Years - 70 Years | Changhai Hospital | |
| Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment | NCT02449551 | Advanced Gastri... | Volitinib | 20 Years - | Samsung Medical Center | |
| Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma | NCT05041153 | Advanced Gastri... Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Gast... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Unresectable Ga... Unresectable Ga... | Lenvatinib Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer | NCT06028737 | Gastric Cancer Stomach Cancer GastroEsophagea... Gastric Adenoca... Gastroesophagea... Advanced Gastri... Gastric Neoplas... Stomach Neoplas... Gastrointestina... Advanced Gastro... Advanced Gastri... | Docetaxel Oxaliplatin Leucovorin Fluorouracil | 18 Years - 80 Years | Ukrainian Society of Clinical Oncology | |
| Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors | NCT00511576 | Breast Cancer Lung Cancer Pulmonary Cance... Non-Small-Cell ... Prostate Cancer Prostatic Cance... Gastric Cancer Stomach Cancer | MGCD0103 & Doce... | 18 Years - | Mirati Therapeutics Inc. | |
| PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer | NCT04174339 | Advanced Gastri... | Camrelizumab Apatinib Mesyla... POF | 18 Years - 70 Years | Fujian Cancer Hospital | |
| PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma | NCT02615730 | Advanced Gastri... | GSK2636771 Paclitaxel | 19 Years - | Yonsei University | |
| PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer | NCT04174339 | Advanced Gastri... | Camrelizumab Apatinib Mesyla... POF | 18 Years - 70 Years | Fujian Cancer Hospital | |
| PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma | NCT02615730 | Advanced Gastri... | GSK2636771 Paclitaxel | 19 Years - | Yonsei University | |
| Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment | NCT02447406 | Advanced Gastri... | AZD6094 docetaxel | - 20 Years | Samsung Medical Center | |
| A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab | NCT05583383 | Advanced Gastri... | camrelizumab | 18 Years - 75 Years | Henan Cancer Hospital | |
| Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment | NCT02447380 | Advanced Gastri... | AZD6094 Docetaxel | - 20 Years | Samsung Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
